Latest filing published 13 Aug 2026 for Amneal Pharmaceuticals, Inc., €2.2M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Nikita Shah, listed as chief executive, appears in our data through filings on Amneal Pharmaceuticals, Inc. shares, published by SEC (Form 4). The record holds 21 filings, for trades running from 7 May 2021 to 12 August 2026.
Every open-market trade on record is a sale: 7 sales worth €5.2M. Outside the open market, there are 1 share grant and 13 option exercises. So far in 2026, the count stands at no purchases and 1 sale.
The record was last updated on 13 August 2026 with an open-market sale (€2.2M) in Amneal Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
21 of 21 declarations